General Information of Drug (ID: DMR5DYK)

Drug Name
2,4-Dichlorobenzenemethanethiol Drug Info
Synonyms
2,4-Dichlorobenzyl mercaptan; 59293-67-3; (2,4-Dichlorophenyl)methanethiol; 2,4-Dichlorobenzylmercaptan; 2,4-dichlorophenylmethanethiol; 2,4-Dichlorobenzenemethanethiol; 2,4-Dichloro-alpha-toluenethiol; 2,4-Dichlorotoluene-alpha-thiol; Benzenemethanethiol, 2,4-dichloro-; CHEMBL1224561; ZSPXTTVUJDSRNJ-UHFFFAOYSA-N; NSC33218; EINECS 261-687-2; AI3-31458; AC1Q3MDQ; ACMC-1B9KZ; AC1L3V0Z; SCHEMBL1802752; 2,4-Dichlorothiobenzyl Alcohol; ZSPXTTVUJDSRNJ-UHFFFAOYSA-; CTK5A9733; DTXSID70208016; MolPort-004-354-551
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
95756
CAS Number
CAS 59293-67-3
TTD Drug ID
DMR5DYK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [2]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [3]
BMS-986205 DM3MAYQ Melanoma 2C30 Phase 3 [4]
INCB24360 DMIJGT9 Urothelial carcinoma 2C92.0 Phase 3 [5]
NLG8189 DM0798Z Melanoma 2C30 Phase 2/3 [4]
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
KHK2455 DMLSUQ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
LY3381916 DMONZ1L Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PF-06840003 DMOX6EJ Glioma 2A00.0 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [1]

References

1 S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9.
2 Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
3 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Incyte. Product Development Pipeline.
6 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
7 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)